Education and Training
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Oseltamivir Phosphate
- drug: ADS-8902
Eligibility
Inclusion Criteria:
- Confirmed influenza A by rapid antigen testing
- Immunocompromised as defined by recent solid organ or hematopoietic transplant,
chronic graft vs. host disease, taking at least 2 immunosuppressants, undergoing
chemotherapy, taking high dose chemotherapeutics, HIV positive
- Clinical diagnosis of influenza
- Onset of illness within 5 days
- Male and female subjects agree to contraception through 24 weeks after last dose
Exclusion Criteria:
- Received more than 1 dose of antiviral agents
- Critically ill
- Creatinine clearance less than 80 mg/mL
- Females who are pregnant and males whose female partners are pregnant
- Received live attenuated virus vaccine within 3 weeks
Ages Eligible for Study
1 Year - 65 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
650-723-0822
Not Recruiting